Vaxcyte stock gains 1.36 percent ahead of October data

Vaxcyte, Inc. (US92242T1016) closed at USD 58.92 on Nasdaq on September 21, 2026, gaining 1.36 percent from the prior close of USD 58.13. The next measurable catalyst is the expected late-October clinical update for VAX-31, the company's 31-valent pneumococcal conjugate vaccine.

VAX-31 data set the timetable

According to Zacks on September 22, 2026, Vaxcyte expects top-line safety, tolerability and immunogenicity data from the phase III OPUS-1 study by the end of October 2026. The study evaluates VAX-31 for the prevention of invasive pneumococcal disease and pneumonia in adults.

The comparison for shareholders is between a defined clinical timetable and the stock's current valuation. At USD 58.92, the shares stood USD 6.08 below the reported 52-week high of USD 65.00 and USD 27.03 above the 52-week low of USD 31.89 on the September 21 market snapshot. That places the closing price 9.35 percent below the high and 84.73 percent above the low.

Market value remains substantial

Yahoo Finance reported a market capitalization of USD 8.768 billion and trading volume of 1,124,393 shares for the September 21, 2026 snapshot. The session range was USD 57.62 to USD 60.53, a USD 2.91 spread around the close.

The numbers show why the October readout matters: the company has an equity value measured in billions, while the next major operating milestone is clinical rather than revenue-driven. A favorable or unfavorable safety and immunogenicity result could therefore change how the market weighs the pipeline, although the outcome itself remains an event risk rather than a financial result.

Closing price stays below yearly high

Vaxcyte stock closed at USD 58.92 on Nasdaq on September 21, 2026, up 1.36 percent from the previous close. The same dated snapshot recorded a 52-week range of USD 31.89 to USD 65.00, market capitalization of USD 8.768 billion and volume of 1,124,393 shares.

More news and analyses on Vaxcyte stock